indications for glp-1 agonists A glimpse of the future: new molecules and GLP1 💡💉 The Role of Glucagon-Like Peptide-1

Patients with a BMI of 27 or higher may also qualify if they have a history of certain conditions including prediabetes, prior heart attack, or stroke

Activation of GLP-1R engages cAMP/PKA and PI3K/Akt pathways overlapping with insulin receptor signaling

approved final version of manuscript

A systematic review and meta-analysis of the available RCT data showed that retatrutide-treated participants achieved a mean body weight reduction of 10.66 kg and a BMI reduction of 4.53 kg/m, with significant proportions achieving weight loss thresholds of 5%, 10%, 15%, and 20% versus placebo

doi: 10.1038/s41366-025-01859-6

doi: 10.1016/j.bbrc.2009.12.075